Phase II Data May Be Good Sign For 8mg Aflibercept, But Will Payers Bite?
There are concerns that even with better efficacy and dosing versus Eylea and biosimilars, payers may impose step-edits on Regeneron’s new high-dose version.
You may also be interested in...
THR-687’s failure in Phase II marks the second drug to flunk in the disease after a Phase IIa study of THR-317 showed disappointing results in 2019, but THR-149 has shown some encouraging data.
Monthly dosing remains a possibility in wet age-related macular degeneration, though diabetic macular edema and retinal vein occlusion look more promising.
Two veterans of the ophthalmology field are reuniting to launch a portfolio-based biotech company EyeBio.